A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines

Molecular Medicine Reports

Volumn 1, Issue 3, 2008, Pages 429-434

  Mori Iwamoto, Sayaka ^a   Kuramitsu, Yasuhiro ^a   Ryozawa, Shomei ^a   Taba, Kumiko ^a   Fujimoto, Masanori ^a   Okita, Kiwamu ^b   Nakamura, Kazuyuki ^a   Sakaida, Isao ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Shimonoseki Kosei Hospital   (Japan)

Author keywords

Drug resistant; Gemcitabine; Heat shock protein 27; Nucleophosmin; Pancreatic cancer; Proteomics

Indexed keywords

CELL PROTEIN; GEMCITABINE; HEAT SHOCK PROTEIN 27; NUCLEOPHOSMIN;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; LIQUID CHROMATOGRAPHY; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEOMICS; TANDEM MASS SPECTROMETRY; TUMOR CELL; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

EID: 69249144061     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.1.3.429     Document Type: Article

References (33)

1. Williamson RC: Pancreatic cancer: the greatest oncological challenge. Br Med J (Clin Res Ed) 13: 445-446, 1988.
2. Gordis L and Gold EB: Epidemiology of pancreatic cancer. World J Surg 8: 808-821, 1984.
3. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1977.
4. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G and Blatter J: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 1-5, 1996. (Pubitemid 26026268)
5. Bold RJ, Chandra J and McConkey DJ: Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol 6: 279-285, 1999. (Pubitemid 29221014)
6. Shi X, Liu S, Kleeff J, Friess H and Buchler MW: Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 62: 354-362, 2002. (Pubitemid 34914105)
7. Cantwell BM, Bozzino JM, Corris P and Harris AL: The multidrug resistant phenotype in clinical practice: evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer. Eur J Cancer Clin Oncol 24: 123-129, 1988. (Pubitemid 18051175)
8. Licht T, Fiebig HH, Bross KJ, Herrmann F, Berger DP, Shoemaker R and Mertelsmann R: Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro. Int J Cancer 49: 630-637, 1991.
9. Kato S, Nishimura J, Yufu Y, Ideguchi H, Umemura T and Nawata H: Modulation of expression of multidrug resistance gene (mdr-1) by adriamycin. FEBS Lett 308: 175-178, 1992.
10. Togawa A, Ito H, Kimura F, et al: Establishment of gemcitabine-resistant human pancreatic cancer cells and effect of brefeldin-a on the resistant cell line. Pancreas 27: 220-224, 2003. (Pubitemid 37205867)
11. Bergman AM, Pinedo HM, Talianidis I, Veerman G, Loves WJ, van der Wilt CL and Peters GJ: Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer 88: 1963-1970, 2003.
12. Erkan M, Kleeff J, Esposito I, et al: Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 24: 4421-4432, 2005. (Pubitemid 40961765)
13. Rauchwerger DR, Firby PS, Hedley DW and Moore MJ: Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 60: 6075-6079, 2000.
14. Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW and Whang EE: A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells. Cancer Res 64: 3987-3993, 2004. (Pubitemid 38697314)
15. Maehara S, Tanaka S, Shimada M, Shirabe K, Saito Y, Takahashi K and Maehara Y: Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells. Int J Cancer 112: 184-189, 2004. (Pubitemid 39244357)
16. Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE: Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 10: 2307-2318, 2004. (Pubitemid 38445688)
17. Arrigo AP: Hsp27: novel regulator of intracellular redox state. IUBMB Life 52: 303-307, 2001.
18. Concannon CG, Gorman AM and Samali A: On the role of Hsp27 in regulating apoptosis. Apoptosis 8: 61-70, 2003.
19. Garrido C, Bruey JM, Fromentin A, Hammann A, Arrigo AP and Solary E: HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J 13: 2061-2070, 1999. (Pubitemid 29517636)
20. Samali A, Robertson JD, Peterson E, et al: Hsp27 protects mitochondria of thermotolerant cells against apoptotic stimuli. Cell Stress Chaperones 6: 49-58, 2001. (Pubitemid 32275329)
21. Hansen RK, Parra I, Lemieux P, Oesterreich S, Hilsenbeck SG and Fuqua SA: Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat 56: 187-196, 1999. (Pubitemid 29494836)
22. Gibbons NB, Watson RW, Coffey RN, Brady HP and Fitzpatrick JM: Heat-shock proteins inhibit induction of prostate cancer cell apoptosis. Prostate 45: 58-65, 2000. (Pubitemid 30679645)
23. Urbani A, Poland J, Bernardini S, et al: A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines. Proteomics 5: 796-804, 2005. (Pubitemid 40316064)
24. Masashi T, Eiki N, Hirotoshi H, et al: Heat shock protein 27 is involved in acquisition of 5-fluorouracil resistance in human colon cancer. Proceedings of 67th annual meeting of the Japanese Cancer Association 425, 2005.
25. Herrera JE, Savkou R and Olson MO: The ribonuclease activity of nucleolar protein B23. Nucleic Acids Res 23: 3974-3979, 1995.
26. Okuwaki M, Matsumoto K, Tsujimoto M and Nagata K: Function of nucleophosmin/B23, a nucleolar acidic protein, as a histone chaperone. FEBS Lett 506: 272-276, 2001. (Pubitemid 32964828)
27. Li J, Zhang X, Sejas DP and Pang O: Negative regulation of p53 by nucleophosmin antagonizes stress-induced apoptosis in human normal and malignant hematopoietic cells. Leuk Res 29: 1415-1423, 2005. (Pubitemid 41562244)
28. Liu WH, Hsu CY and Yung BY: Nucleophosmin/B23 regulates the susceptibility of human leukemia HL-60 cells to sodium butyrate-induced apoptosis and inhibition of telomerase activity. Int J Cancer 81: 923-929, 1999.
29. Hsu CY and Yung BY: Over-expression of nucleophosmin/B23 decreases the susceptibility of human leukemia HL-60 cells to retinoic acid-induced differentiation and apoptosis. Int J Cancer 88: 392-400, 2000.
30. Gao H, Jin S, Song Y, et al: B23 regulates GADD45a nuclear translocation and contributes to GADD45a-induced cell cycle G2-M arrest. J Biol Chem 280: 10988-11096, 2005. (Pubitemid 40418401)
31. Friess H, Lu Z, Graber HU, et al: bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 43: 414-421, 1998. (Pubitemid 28414925)
32. Chang GC, Hsu SL, Tsai JR, Wu WJ, Chen CY and Sheu GT: Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol 19: 169-183, 2004.
33. Xu Z, Friess H, Solioz M, Aebi S, Korc M, Kleeff J and Buchler MW: Bcl-x(L) antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. Int J Cancer 94: 268-274, 2001. (Pubitemid 32911423)